{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:34:12Z","timestamp":1794335652195,"version":"4.9.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00208347"],"award-info":[{"award-number":["RS-2023-00208347"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01377-2","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:48:15Z","timestamp":1775742495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CD18-targeted peptide-drug conjugate remodels the immunosuppressive tumor microenvironment of prostate cancer by selective depletion of M2 macrophages"],"prefix":"10.1038","volume":"10","author":[{"given":"Ik-Hwan","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilseob","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heekyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjin","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Jun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunsu","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"1377_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P. Epidemiology of prostate cancer. World J. Oncol. 10, 63\u201389 (2019).","journal-title":"World J. Oncol."},{"key":"1377_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217155","volume":"601","author":"D Liu","year":"2024","unstructured":"Liu, D., Wang, L. & Guo, Y. Advances in and prospects of immunotherapy for prostate cancer. Cancer Lett. 601, 217155 (2024).","journal-title":"Cancer Lett."},{"key":"1377_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.581","volume":"12","author":"C Boibessot","year":"2022","unstructured":"Boibessot, C. et al. Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clin. Transl. Med. 12, e581 (2022).","journal-title":"Clin. Transl. Med."},{"key":"1377_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","volume":"23","author":"S Chen","year":"2021","unstructured":"Chen, S. et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat. Cell Biol. 23, 87\u201398 (2021).","journal-title":"Nat. Cell Biol."},{"key":"1377_CR5","doi-asserted-by":"publisher","first-page":"e148549","DOI":"10.1172\/JCI148549","volume":"132","author":"MJ Watson","year":"2022","unstructured":"Watson, M. J. & Delgoffe, G. M. Fighting in a wasteland: deleterious metabolites and antitumor immunity. J. Clin. Investig. 132, e148549 (2022).","journal-title":"J. Clin. Investig."},{"key":"1377_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202305724","volume":"11","author":"X Bian","year":"2024","unstructured":"Bian, X. et al. Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity. Adv. Sci. 11, 2305724 (2024).","journal-title":"Adv. Sci."},{"key":"1377_CR7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/labinvest.2013.69","volume":"93","author":"CY Liu","year":"2013","unstructured":"Liu, C. Y. et al. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4\/IL-10 signaling pathway. Lab Investig. 93, 844\u2013854 (2013).","journal-title":"Lab Investig."},{"key":"1377_CR8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41391-024-00825-z","volume":"28","author":"B Fang","year":"2025","unstructured":"Fang, B. et al. Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer. Prostate Cancer Prostatic Dis. 28, 260\u2013269 (2025).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1377_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. npj Precis. Oncol. 8, 31 (2024).","journal-title":"npj Precis. Oncol."},{"key":"1377_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8580043","volume":"2022","author":"C Han","year":"2022","unstructured":"Han, C. et al. The roles of tumor-associated macrophages in prostate cancer. J. Oncol. 2022, 8580043 (2022).","journal-title":"J. Oncol."},{"key":"1377_CR11","doi-asserted-by":"publisher","first-page":"24560","DOI":"10.1074\/jbc.M114.571620","volume":"289","author":"FN Soki","year":"2014","unstructured":"Soki, F. N. et al. Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis*. J. Biol. Chem. 289, 24560\u201324572 (2014).","journal-title":"J. Biol. Chem."},{"key":"1377_CR12","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/andr.12783","volume":"8","author":"H Werneck-Gomes","year":"2020","unstructured":"Werneck-Gomes, H. et al. Tumor-Associated Macrophages (TAM) are recruited to the aging prostate epithelial lesions and become intermingled with basal cells. Andrology 8, 1375\u20131386 (2020).","journal-title":"Andrology"},{"key":"1377_CR13","doi-asserted-by":"publisher","first-page":"e006020","DOI":"10.1136\/jitc-2022-006020","volume":"11","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6. J. Immunother. Cancer 11, e006020 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1377_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J. Exp. Clin. Cancer Res. 44, 145 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1377_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2398195","volume":"56","author":"Y Ou","year":"2024","unstructured":"Ou, Y. et al. Comprehensive scRNA-seq analysis to identify new markers of M2 macrophages for predicting the prognosis of prostate cancer. Ann. Med. 56, 2398195 (2024).","journal-title":"Ann. Med."},{"key":"1377_CR16","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","volume":"22","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier, A. J. & Elsawa, S. F. Macrophage polarization states in the tumor microenvironment. Int. J. Mol. Sci. 22, 6995 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1377_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110876","volume":"39","author":"L Wen","year":"2022","unstructured":"Wen, L. et al. A humanized \u03b22 integrin knockin mouse reveals localized intra- and extravascular neutrophil integrin activation in vivo. Cell Rep. 39, 110876 (2022).","journal-title":"Cell Rep."},{"key":"1377_CR18","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1084\/jem.181.4.1473","volume":"181","author":"RR Ingalls","year":"1995","unstructured":"Ingalls, R. R. & Golenbock, D. T. CD11c\/CD18, a transmembrane signaling receptor for lipopolysaccharide. J. Exp. Med. 181, 1473\u20131479 (1995).","journal-title":"J. Exp. Med."},{"key":"1377_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13046-025-03510-8","volume":"44","author":"S Hu","year":"2025","unstructured":"Hu, S. et al. COL10A1+ fibroblasts promote colorectal cancer metastasis and M2 macrophage polarization with pan-cancer relevance. J. Exp. Clin. Cancer Res. 44, 243 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1377_CR20","doi-asserted-by":"publisher","first-page":"e011422","DOI":"10.1136\/jitc-2024-011422","volume":"13","author":"IH Han","year":"2025","unstructured":"Han, I. H. et al. Conformation-sensitive targeting of CD18 depletes M2-like tumor-associated macrophages resulting in inhibition of solid tumor progression. J. Immunother. Cancer 13, e011422 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1377_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep03468","volume":"3","author":"W-H Chen","year":"2013","unstructured":"Chen, W.-H. et al. Dual-targeting pro-apoptotic peptide for programmed cancer cell death via specific mitochondria damage. Sci. Rep. 3, 3468 (2013).","journal-title":"Sci. Rep."},{"key":"1377_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"1377_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1398109","volume":"15","author":"L San-Jose Manso","year":"2024","unstructured":"San-Jose Manso, L. et al. Immunome profiling in prostate cancer: a guide for clinicians. Front. Immunol. 15, 1398109 (2024).","journal-title":"Front. Immunol."},{"key":"1377_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27322-4","volume":"13","author":"H Song","year":"2022","unstructured":"Song, H. et al. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat. Commun. 13, 141 (2022).","journal-title":"Nat. Commun."},{"key":"1377_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110132","volume":"37","author":"ZK Tuong","year":"2021","unstructured":"Tuong, Z. K. et al. Resolving the immune landscape of human prostate at a single-cell level in health and cancer. Cell Rep. 37, 110132 (2021).","journal-title":"Cell Rep."},{"key":"1377_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.tips.2019.08.003","volume":"40","author":"MJ Sis","year":"2019","unstructured":"Sis, M. J. & Webber, M. J. Drug delivery with designed peptide assemblies. Trends Pharmacol. Sci. 40, 747\u2013762 (2019).","journal-title":"Trends Pharmacol. Sci."},{"key":"1377_CR27","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1021\/acs.biomac.9b01073","volume":"20","author":"Z Jiang","year":"2019","unstructured":"Jiang, Z., He, H., Liu, H. & Thayumanavan, S. Cellular uptake evaluation of amphiphilic polymer assemblies: importance of interplay between pharmacological and genetic approaches. Biomacromolecules 20, 4407\u20134418 (2019).","journal-title":"Biomacromolecules"},{"key":"1377_CR28","doi-asserted-by":"publisher","first-page":"15751","DOI":"10.3390\/ijms232415751","volume":"23","author":"S Kim","year":"2022","unstructured":"Kim, S., Choi, I., Han, I. H. & Bae, H. Enhanced therapeutic effect of optimized melittin-dKLA, a peptide agent targeting M2-like tumor-associated macrophages in triple-negative breast cancer. Int. J. Mol. Sci. 23, 15751 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1377_CR29","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/hep.31432","volume":"73","author":"J Wu","year":"2021","unstructured":"Wu, J. et al. M2 macrophage-derived exosomes facilitate hcc metastasis by transferring \u03b1(M) \u03b2(2) integrin to tumor cells. Hepatology 73, 1365\u20131380 (2021).","journal-title":"Hepatology"},{"key":"1377_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41423-024-01232-z","volume":"21","author":"J Kzhyshkowska","year":"2024","unstructured":"Kzhyshkowska, J., Shen, J. & Larionova, I. Targeting of TAMs: can we be more clever than cancer cells? Cell. Mol. Immunol. 21, 1376\u20131409 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"1377_CR31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.4049\/jimmunol.1700737","volume":"200","author":"SY Nu\u00f1ez","year":"2018","unstructured":"Nu\u00f1ez, S. Y. et al. Human M2 macrophages limit NK cell effector functions through secretion of TGF-\u03b2 and engagement of CD85j. J. Immunol. 200, 1008\u20131015 (2018).","journal-title":"J. Immunol."},{"key":"1377_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549\u2013555 (2002).","journal-title":"Trends Immunol."},{"key":"1377_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2022.07.004","volume":"67","author":"W Li","year":"2022","unstructured":"Li, W. et al. Correlation between PD-1\/PD-L1 expression and polarization in tumor-associated macrophages: a key player in tumor immunotherapy. Cytokine Growth Factor Rev. 67, 49\u201357 (2022).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1377_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang, X., Wang, J., Lu, D. & Xu, X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct. Target Ther. 6, 75 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"1377_CR35","doi-asserted-by":"publisher","first-page":"9332","DOI":"10.7150\/thno.47137","volume":"10","author":"X Dai","year":"2020","unstructured":"Dai, X. et al. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer. Theranostics 10, 9332\u20139347 (2020).","journal-title":"Theranostics"},{"key":"1377_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003093","volume":"9","author":"S Pu","year":"2021","unstructured":"Pu, S. et al. PI3K\u03b1 inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism. J. Immunother. Cancer 9, e003093 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1377_CR37","doi-asserted-by":"publisher","first-page":"1114605","DOI":"10.3389\/fimmu.2023.1114605","volume":"14","author":"M Papanastasatou","year":"2023","unstructured":"Papanastasatou, M. & Verykokakis, M. Innate-like T lymphocytes in chronic liver disease. Front. Immunol. 14, 1114605 (2023).","journal-title":"Front. Immunol."},{"key":"1377_CR38","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/07853890.2021.1924396","volume":"53","author":"Z JiaWei","year":"2021","unstructured":"JiaWei, Z. et al. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Ann. Med. 53, 730\u2013740 (2021).","journal-title":"Ann. Med."},{"key":"1377_CR39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2402903121","volume":"121","author":"G Yu","year":"2024","unstructured":"Yu, G. et al. Prostate cancer\u2013induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone\u2013tumor microenvironment through Wnt pathway\u2013induced M2 macrophage polarization. Proc. Natl. Acad. Sci. USA 121, e2402903121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1377_CR40","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013w14 (2020).","journal-title":"Nucleic Acids Res."},{"key":"1377_CR41","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nbt.3614","volume":"34","author":"Y Kim","year":"2016","unstructured":"Kim, Y. et al. Generation of knockout mice by Cpf1-mediated gene targeting. Nat. Biotechnol. 34, 808\u2013810 (2016).","journal-title":"Nat. Biotechnol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01377-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01377-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01377-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:03:34Z","timestamp":1781172214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01377-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01377-2","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"215"}}